First human tests begin for Huntington's disease drug candidate
NCT ID NCT03787758
Summary
This early-stage study tested the safety and how the body processes SAGE-718, an oral liquid medication being developed for Huntington's disease. It involved a small group of healthy adults and a few patients with Huntington's disease. The main goal was to see if the drug was safe and well-tolerated at different dose levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sage Investigational Site
Long Beach, California, 90806, United States
-
Sage Investigational Site
Marlton, New Jersey, 08053, United States
Conditions
Explore the condition pages connected to this study.